2023 cell and gene therapy industry survey

Advancing the future of personalized medicine

What’s ahead for the cell and gene therapy (CGT) market? Deloitte’s survey of CGT innovators, health care providers, and contract development and manufacturing organizations (CDMOs) reveals shared optimism for the gene therapy market while identifying areas for caution. Uncover insights to guide decision-making and strategic planning in the future of personalized medicine.

Stakeholders express positive outlook for cell and gene therapy market

Deloitte’s 2023 cell and gene therapy industry survey aimed to address the scarcity of CGT-specific information regarding past and future challenges across the value chain. The survey highlighted the key challenges and opportunities that organizations, their partners, and the broader cell and gene therapy market face.

When examining the sentiments expressed by stakeholders, CGT innovators and health care providers had a positive sentiment about the industry over the past 12–18 months. Approximately 86% of CGT innovators and 83% of health care providers felt that this period had been positive for CGTs. In contrast, only 66% of CDMOs shared the same sentiment.

However, in looking ahead to the next 12–18 months, there is a more positive outlook across all stakeholder groups. CGT innovators (93%), health care providers (86%), and CDMOs (83%) expressed optimism, believing that the future will bring positive developments for the industry. Respondents had a more favorable outlook for gene therapies than autologous and allogeneic cell therapies when considering the next 12–18 months.

Cell and gene therapy insights

Explore key findings on the cell and gene therapy market

Our survey aimed to address the scarcity of information across five key areas: research and development, manufacturing, commercialization, data and digital capabilities, and regulatory. Explore our findings below:

Emerging opportunities in the cell and gene therapy market

Overall, responses tell a story of positive sentiment for the CGT industry, with most CGT leaders feeling positive about the past and expressing optimism for the future. However, differences emerged when considering specific therapy types, with gene therapies garnering the most positive outlook. While acknowledging the challenges ahead, the respondents expressed optimism about the potential of CGTs to transform health care and improve patient outcomes. The insights gathered from this survey highlight the challenges across various aspects of the CGT value chain, but also the collective industry sentiment about the potential of these therapies in the years to come.

By navigating the hurdles and capitalizing on emerging opportunities, the industry can continue to advance the development of these transformational treatments and the broader health care industry.

Are you ready to digitize your therapy's orchestration?

The CGT supply chain is more complex than traditional pharma – requiring more stakeholders and touchpoints. Organizations can simplify and manage this end-to-end journey using ConvergeHEALTH™ CGT Vantage, a configurable software-as-a-service solution designed to orchestrate the end-to-end patient treatment journey for cell and gene therapies.

Learn more

Get in touch

Hussain Mooraj
Principal, NextGen Therapies Practice Lead
Deloitte Consulting
+1 508 561 9266

Amit Agarwal
Managing Director
Deloitte Consulting LLP
+1 415 783 6691


Jessica Faust
Managing Director
Deloitte Consulting LLP
+1 617 813 4259

Rajesh Singh
Managing Director
Deloitte Consulting LLP
+1 973 602 6296


Jennifer Rabin
NextGen Therapies Specialist Leader
Deloitte Consulting LLP
+1 202 897 9497

Alex Haig
NextGen Therapies Consultant
Deloitte Consulting LLP
+1 646 203 1468


Fullwidth SCC. Do not delete! This box/component contains JavaScript that is needed on this page. This message will not be visible when page is activated.

Did you find this useful?